Finally, IL-6 is recognized as one of the main drivers of cachexia and muscle atrophy during cancer [21,23], as administration of neutralizing IL-6 antibodies in C26 mice prevents the muscular atrophy despite a slight increase in tumor mass [21]. This evidence concerns the gene IL6 and neoplasm.